Your browser doesn't support javascript.
loading
White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Eloyan, Ani; Thangarajah, Maryanne; An, Na; Borowski, Bret J; Reddy, Ashritha L; Aisen, Paul; Dage, Jeffrey L; Foroud, Tatiana; Ghetti, Bernardino; Griffin, Percy; Hammers, Dustin; Iaccarino, Leonardo; Jack, Clifford R; Kirby, Kala; Kramer, Joel; Koeppe, Robert; Kukull, Walter A; La Joie, Renaud; Mundada, Nidhi S; Murray, Melissa E; Nudelman, Kelly; Rumbaugh, Malia; Soleimani-Meigooni, David N; Toga, Arthur; Touroutoglou, Alexandra; Atri, Alireza; Day, Gregory S; Duara, Ranjan; Graff-Radford, Neill R; Honig, Lawrence S; Jones, David T; Masdeu, Joseph; Mendez, Mario F; Musiek, Erik; Onyike, Chiadi U; Rogalski, Emily; Salloway, Stephen; Sha, Sharon; Turner, Raymond S; Wingo, Thomas S; Wolk, David A; Womack, Kyle; Beckett, Laurel; Gao, Sujuan; Carrillo, Maria C; Rabinovici, Gil; Apostolova, Liana G; Dickerson, Brad; Vemuri, Prashanthi.
Afiliação
  • Eloyan A; Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • Thangarajah M; Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • An N; Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • Borowski BJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Reddy AL; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Aisen P; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Dage JL; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Foroud T; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Ghetti B; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Griffin P; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Hammers D; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Iaccarino L; Department of Pathology & Laboratory Medicine Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Jack CR; Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
  • Kirby K; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Kramer J; Department of Neurology, University of California-San Francisco, San Francisco, California, USA.
  • Koeppe R; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Kukull WA; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • La Joie R; Department of Neurology, University of California-San Francisco, San Francisco, California, USA.
  • Mundada NS; Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
  • Murray ME; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Nudelman K; Department of Neurology, University of California-San Francisco, San Francisco, California, USA.
  • Rumbaugh M; Department of Neurology, University of California-San Francisco, San Francisco, California, USA.
  • Soleimani-Meigooni DN; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Toga A; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Touroutoglou A; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Atri A; Department of Neurology, University of California-San Francisco, San Francisco, California, USA.
  • Day GS; Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
  • Duara R; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Graff-Radford NR; Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Honig LS; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Jones DT; Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
  • Masdeu J; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Mendez MF; Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
  • Musiek E; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Onyike CU; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Rogalski E; Nantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
  • Salloway S; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Sha S; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Turner RS; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Wingo TS; Department of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Wolk DA; Department of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
  • Womack K; Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
  • Beckett L; Department of Neurology, Georgetown University, Washington D.C., USA.
  • Gao S; Department of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Carrillo MC; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Rabinovici G; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Apostolova LG; Department of Public Health Sciences, University of California-Davis, Davis, California, USA.
  • Dickerson B; Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Vemuri P; Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
Alzheimers Dement ; 19 Suppl 9: S89-S97, 2023 11.
Article em En | MEDLINE | ID: mdl-37491599
ABSTRACT

INTRODUCTION:

We compared white matter hyperintensities (WMHs) in early-onset Alzheimer's disease (EOAD) with cognitively normal (CN) and early-onset amyloid-negative cognitively impaired (EOnonAD) groups in the Longitudinal Early-Onset Alzheimer's Disease Study.

METHODS:

We investigated the role of increased WMH in cognition and amyloid and tau burden. We compared WMH burden of 205 EOAD, 68 EOnonAD, and 89 CN participants in lobar regions using t-tests and analyses of covariance. Linear regression analyses were used to investigate the association between WMH and cognitive impairment and that between amyloid and tau burden.

RESULTS:

EOAD showed greater WMHs compared with CN and EOnonAD participants across all regions with no significant differences between CN and EOnonAD groups. Greater WMHs were associated with worse cognition. Tau burden was positively associated with WMH burden in the EOAD group.

DISCUSSION:

EOAD consistently showed higher WMH volumes. Overall, greater WMHs were associated with worse cognition and higher tau burden in EOAD. HIGHLIGHTS This study represents a comprehensive characterization of WMHs in sporadic EOAD. WMH volumes are associated with tau burden from positron emission tomography (PET) in EOAD, suggesting WMHs are correlated with increasing burden of AD. Greater WMH volumes are associated with worse performance on global cognitive tests. EOAD participants have higher WMH volumes compared with CN and early-onset amyloid-negative cognitively impaired (EOnonAD) groups across all brain regions.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva / Substância Branca Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Disfunção Cognitiva / Substância Branca Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Alzheimers Dement Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos